Elevation of hepatic microsomal epoxide hydrolase activity by 2-acetylaminofluorene: strain and species differences

M. Elizabeth Graichen and John G. Dent

Department of Biochemical Toxicology, Chemical Industry Institute of Toxicology, Research Triangle Park, NC 27709, USA.

1Present address: Department of Drug Metabolism, Smith Kline & French Laboratories, PO Box 7929, Philadelphia, PA 19101, USA.

2To whom reprint requests should be sent.

Hepatocarcinogens have been shown to cause marked elevation of hepatic microsomal epoxide hydrolase activity in the rat at short intervals after administration. The present studies were designed to characterize 2-acetylaminofluorene (AAF) mediated epoxide hydrolase elevation and to investigate the relationship between epoxide hydrolase increases, AAF metabolism, and hepatocarcinogenicity. Oral or i.p. administration of AAF to F-344 rats produced log-linear dose-response curves for epoxide hydrolase elevation, measured with either benzo[a]pyrene-4,5-oxide or styrene oxide substrate. Following a single dose of AAF (35 mg/kg), epoxide hydrolase activity was maximally increased (560% of control) within 48 h, and the activity declined slowly, with a half-life of 17.5 days. Co-treatment with actinomycin D effectively blocked the AAF dependent increase in epoxide hydrolase, suggesting that de novo protein synthesis is associated with the increase in enzyme activity. Dose-response curves for epoxide hydrolase induction by AAF, N-hydroxy-2-acetylaminofluorene (N-OH-AAF), and 2-aminofluorene were compared, and the potencies for increasing epoxide hydrolase activity reflected the relative hepatocarcinogenic potentials of these agents. In mice, which are resistant to the hepatocarcinogenic action of AAF and deficient in AAF-N-hydroxylase activity, AAF caused no significant increase in hepatic microsomal epoxide hydrolase activity. Similarly, in Cotton rats and guinea pigs, which are lacking in ability to metabolize N-OH-AAF, including microsomal deacetylase and cytosolic N-O acetyltransferase and sulfotransferase potentials of these agents. In mice, which are resistant to the hepatocarcinogenic action of AAF and deficient in AAF-N-hydroxylase activity, AAF caused no significant increase in hepatic microsomal epoxide hydrolase activity. Similarly, in Cotton rats and guinea pigs, which are lacking in ability to metabolize N-OH-AAF, including microsomal deacetylase and cytosolic N-O acetyltransferase and sulfotransferase activities (1–5). The elevation of epoxide hydrolase activity has been observed following treatment with a wide variety of hepatocarcinogens and is dose-related. Comparison of the slopes of the log-linear dose response curves for increases in epoxide hydrolase elicited by several hepatocarcinogens of diverse structure showed them to be similar, suggesting that the increases in epoxide hydrolase occur through a common mechanism. Furthermore, a correlation has been suggested between hepatocarcinogenic potency and potency in increasing epoxide hydrolase activity (1).

Okita and co-workers (6) demonstrated the presence of an antigenic component, termed preneoplastic or PN-antigen*, in phenotypically altered foci of liver cells induced by chemical carcinogens. Purification of PN-antigen led to its identification as epoxide hydrolase (7,8). More recently, Lin et al. (9) suggested that PN-antigen and epoxide hydrolase are different proteins. While the relationship between PN-antigen and epoxide hydrolase remains to be resolved, it is evident that phenotypically altered foci of hepatocytes induced by chemical carcinogens contain elevated quantities of epoxide hydrolase (8). Elevated quantities of epoxide hydrolase have been demonstrated immunocytochemically in hyperplastic nodules (10,11), and increased epoxide hydrolase activity has been observed in rats subjected to various promoting regimens for induction of hyperplastic nodules (12) and in several hepatomas (8,13).

The metabolic activation and carcinogenicity of 2-acetylaminofluorene (AAF) have been extensively studied (for reviews see 14—16). The putative proximate carcinogenic metabolite N-hydroxy-2-acetylaminofluorene (N-OH-AAF) is formed by the hepatic cytochrome P-450 mixed-function oxidase system (17). Several enzymes are known to further metabolize N-OH-AAF, including microsomal deacetylase and cytosolic N-O acetyltransferase and sulfotransferase (18—20). Species and strain differences in the metabolic activation of AAF have been reported, and are correlated with susceptibility to its carcinogenic effects (14,21—23).

The objectives of the studies described here were to utilize the known species and strain differences in metabolism of AAF and sensitivity to AAF-induced hepatocarcinogenicity to investigate the mechanism of hepatic microsomal epoxide hydrolase elevation by this compound.

Introduction

Short-term exposure of rats to hepatocarcinogens has been shown to result in a marked increase in hepatic microsomal epoxide hydrolase (EC 3.3.2.3) activity, while having little effect on cytochrome P-450-dependent mixed-function oxidase activities (1–5). The elevation of epoxide hydrolase activity has been observed following treatment with a wide variety of hepatocarcinogens and is dose-related. Comparison of the slopes of the log-linear dose response curves for increases in epoxide hydrolase elicited by several hepatocarcinogens of diverse structure showed them to be similar, suggesting that the increases in epoxide hydrolase occur through a common mechanism. Furthermore, a correlation has been suggested between hepatocarcinogenic potency and potency in increasing epoxide hydrolase activity (1).

Materials and methods

Chemicals

AAF (95–97%), and 2-aminofluorene (AF) (98%) were purchased from Aldrich Chemical Company, Milwaukee, WI. Actinomycin D (AD) and bovine serum albumin were obtained from Sigma Chemical Company, St. Louis, MO. Aflatoxin B1 (AFB) was purchased from Calbiochem-Behring Corporation, La Jolla, CA. Sodium phenobarbital (PB) was obtained from Mallinckrodt, St. Louis, MO. Methoxyflurane was purchased from Pitman-Moore, Inc., Washington Crossing, NJ. [G-3H]Benzo[a]pyrene-4,5-oxide (BPO) and [U-14C]methyl red were prepared by Midwest Research Institute, Kansas City, MO. N-hydroxy-2-acetylaminofluorene (N-OH-AAF) was generously provided by Dr. F.A.Beland, National Center for Toxicological Research, Jefferson, AR; [7-3H]pyrene oxide (SO) was a gift from Prof.
F.-Oesch, Institute of Pharmacology, Mainz, FRG. All other chemicals were the best grades commercially available.

**Animals and treatments**

CDF® (F-344)/CrlBR rats, DBA/2NCrBR and C57BL/6NCrBR mice, and Hartley Cr(CrHR)BR guinea pigs were purchased from Charles River Breeding Laboratories, Inc., Kingston, NY. Cotton rats originated from a breeding pair obtained from the National Institutes of Health, Bethesda, MD. Sera from sentinel animals of the same age, sex, and strain, and maintained in the same rooms were tested weekly (Microbiological Associates, Bethesda, MD) and found negative to titers to a range of viruses. [Rats were screened for Reovirus type 3, pneumonia virus of mice, mouse encephalomyelitis, Kilham rat virus, Toolan’s H-1, Sendai, mouse adenovirus, lymphocytic choriomeningitis, mouse hepatitis virus, and rat corona virus; guinea pigs for simian virus 5, Reovirus type 3, Sendai, pneumonia virus of mice, and lymphocytic choriomeningitis; mice for Reovirus type 3, mouse encephalomyelitis, K virus, polyoma virus, Sendai, encephalomyelitis, pneumonia virus of mice, minute virus of mice, mouse adenovirus, mouse hepatitis virus, and lymphocytic choriomeningitis.] The animals were housed in temperature (21 ± 3°C) and humidity (50 + 10%) controlled rooms, with a 12 h light cycle, and with free access to food (certified NIH-07 open-formula diet, Ziegler Bros. Inc., Gardners, PA (rats and mice) or Purina guinea pig Chow,Ralston Purina Co., St. Louis, MO) and tap water.

All animals were acclimated for 2 weeks prior to use, by which time the mice, guinea pigs, and F-344 rats were 9—10 weeks of age. Due to the difficulties involved in raising Cotton rats, these animals were between 8 and 30 weeks of age when treatments began. Older and younger rats were mixed within treatment groups, and no age-related variations in enzymatic activity were noted in control or treated animals.

The majority of treatments were administered by i.p. injection (1 or 2 ml/kg in DMSO) or by gavage (10 ml/kg in corn oil). Control animals received the vehicle alone. Cotton rats were lightly anesthetized with CO₂ before injection. For dietary administration, animals were fed a semisynthetic diet (24) containing 0.02% AAF, purchased from Bio-Serve, Inc., Frenchtown, NJ. Control animals received the semisynthetic basal diet.

**Preparation of liver subcellular fractions and enzyme assays**

Animals were killed by cervical dislocation or by exsanguination under methoxyflurane anesthesia. Livers were quickly removed and washed in ice-cold 1.15% KCl. After weighing, the livers were coarsely chopped, washed in ice-cold 1.15% KCl, 20 mM Tris-HCl, pH 7.4, and homogenized in 3 volumes of this buffer in a teflon-glass Potter-Elvehjem homogenizer. Postmitochondrial supernatant (PMS) was prepared by centrifugation of the liver homogenate at 10 000 g for 20 min. In some studies, microsomes were isolated by centrifugation of the PMS for 100 000 g h, followed by resuspension in 20 mM Tris-HCl (pH 7.4) containing 250 mM sucrose and 5.4 mM EDTA. Subcellular fractions were stored at −80°C.

Epoxide hydrolase activity was measured using BPO or SO substrate. After incubation, the reaction products were separated by extraction (mice) (25,26) or by t.l.c. (all other experiments) (27). DT-diaphorase (EC 1.6.99.2) activity was assayed by measuring the rate of reduction of methyl red (28). Protein concentrations were determined by the biuret method (29) using American Monitors Total Protein Kit (American Monitor Co., Indianapolis, IN) with bovine serum albumin as a standard.

**Statistical analysis**

Where appropriate, data were evaluated by a one-way analysis of variance. Where significant F values were obtained, tests for differences between treatment means were performed using the Student-Newman-Keuls procedure (30).

**Results**

**Time course and dose-response relationship for epoxide hydrolase elevation**

Following administration of a single oral dose of AAF (35 mg/kg) to male F-344 rats, hepatic microsomal epoxide hydrolase activity reached a peak level (560% of control) at 48 h (Figure 1). The enzyme activity declined very slowly, in a log-linear fashion, with a half-life of 17.5 days. At 32 days following treatment, the epoxide hydrolase activity was still nearly twice control levels.

A single i.p. injection of F-344 rats with AAF resulted in a log-linear dose-related increase in epoxide hydrolase activity measured 48 h later, to a maximum of 450% control at a dose of 100 mg/kg (Figure 2). The pattern of increased enzyme activity was identical whether measured with BPO or SO substrate (data not shown); the ED₅₀ for epoxide hydrolase elevation following a single dose was 20 mg/kg.

When rats were treated with three consecutive daily doses
of AAF, epoxide hydrolase activity measured 48 h after the last dose was again increased in a log-linear, dose-related manner (Figure 3). Oral administration of AAF produced a slightly greater maximal increase in epoxide hydrolase than intraperitoneal administration (570% and 380% control, respectively); however the slope and shape of the dose-response curves were independent of the route of administration. The ED$_{50}$ for epoxide hydrolase elevation following three oral or i.p. doses was 12 mg/kg/day.

Cytosolic DT-diaphorase activity was also increased in a dose-related manner after three treatments with AAF, but the maximal activity attained was only 156% of control at a dose of 100 mg/kg (Figure 4).

**Effect of actinomycin D on AAF-dependent epoxide hydrolase elevation**

Co-administration of AD with AAF inhibited the AAF dependent increase in epoxide hydrolase activity in F-344 rats (Table I). A single dose of 35 mg/kg AAF elicited a 250% increase in epoxide hydrolase activity, but in animals treated with AAF plus AD, epoxide hydrolase activity was not significantly different from control. AD alone had no significant effect on hepatic epoxide hydrolase levels.

**Epoxide hydrolase elevation by compounds structurally related to AAF**

Both N-OH-AAF and AF increased hepatic epoxide hydrolase activity in F-344 rats (Figure 2). N-OH-AAF was a more potent inducer than AAF, with a single dose ED$_{50}$ of 12 mg/kg, assuming a maximal response equal to that obtained with AAF. The maximal response to N-OH-AAF could not be determined as doses above 20 mg/kg were lethal. In contrast, AF at a dose of 240 mg/kg produced only a 2-fold increase in epoxide hydrolase activity.

**Species and strain comparisons in the response to AAF**

Treatment of guinea pigs with three daily doses of AAF as high as 240 mg/kg/day, or with 10 mg/kg N-OH-AAF failed to elicit any significant changes in epoxide hydrolase activity.
Male rats were treated with a single i.p. injection of AAF dissolved in DMSO (2 ml/kg), and were killed 48 h after the last dose. Table II. Effect of AAF or N-OH-AAF treatment on hepatic epoxide hydrolase activity in guinea pigs. Male Hartley guinea pigs received 3 consecutive daily i.p. injections of AAF or N-OH-AAF dissolved in DMSO (2 ml/kg), and were killed 48 h after the last dose.

| Treatment     | Epoxide hydrolase activitya |
|---------------|-----------------------------|
| Control       | 22.16 ± 0.68                |
| AAF, 40 mg/kg | 24.79 ± 1.24                |
| AAF, 80 mg/kg | 24.67 ± 2.71                |
| AAF, 160 mg/kg| 27.56 ± 1.45                |
| AAF, 240 mg/kg| 23.69 ± 2.72                |
| N-OH-AAF, 10 mg/kg| 20.99 ± 2.86               |

a nmol benzo[a]pyrene-4,5-diol formed/mg microsomal protein/min. Mean ± SEM, n = 3.

Table III. Effect of AAF treatment on hepatic activity in mice. Male C57BL6 and DBA2 mice received 0.02% AAF in the diet for 5 days and were sacrificed immediately thereafter. Epoxide hydrolase activity was measured in liver microsomes. Data are presented as mean ± SEM, n = 4 animals.

| Strain | Treatment     | Epoxide hydrolase (BPO)b | Epoxide hydrolase (SO)c |
|--------|---------------|--------------------------|-------------------------|
| C57BL6 | Control       | 0.331 ± 0.066            | 2.53 ± 0.17             |
|        | AAF           | 0.356 ± 0.021            | 3.09 ± 0.28             |
| DBA2   | Control       | 0.284 ± 0.011            | 2.77 ± 0.52             |
|        | AAF           | 0.319 ± 0.012            | 2.59 ± 0.06             |

b nmol benzo[a]pyrene-4,5-diol formed/mg protein/min. c nmol styrene glycol formed/mg protein/min.

Discussion

Treatment of male F-344 rats with AAF elicited a dramatic and dose-related increase in hepatic microsomal epoxide hydrolase activity. The 5- to 6-fold increases measured after only 1 or 3 doses are similar in magnitude to those reported by others (1-4).

The pattern of elevation observed was independent of the substrate used to assay the enzyme or the route of administration. The same pattern of activity was evident when epoxide hydrolase was measured in microsomes or PMS. A cytosolic epoxide hydrolase (31) and a membrane-bound form of the cytosolic enzyme (32) have recently been reported; however these enzymes display no detectable activity with BPO or SO substrate under the assay conditions (pH 9.0) employed in this study (31,32), and thus the epoxide hydrolase activities reported in this study are solely due to the microsomal enzyme.

A dose-related increase in cytosolic DT-diaphorase activity was observed in F-344 rats following AAF treatment, but the maximal increase seen was relatively slight (156% of control). This is in accord with previous observations on the changes in DT-diaphorase activity elicited by other hepatocarcinogens (1). Some workers, however, have noted larger AAF-
dependent increases in DT-diaphorase in Sprague-Dawley rats (3,33), possibly indicating a strain difference in response to this compound.

Following a single oral dose of AAF, epoxide hydrolase activity increased rapidly and then declined slowly, with a half-life of 17.5 days. The persistence of the altered enzyme activity suggests that this change is not the result of enzyme activation. These findings are at variance with those of Aström and DePierre (3), who reported a decline of elevated epoxide hydrolase activity to approximately twice control level by 7 days after the last of 5 daily doses of AAF in Sprague-Dawley rats. This discrepancy may again be a reflection of a strain difference.

Co-treatment of rats with AD, an inhibitor of RNA synthesis (34), effectively blocked the epoxide hydrolase elevation in response to AAF. This result is in accord with the work of Gonzalez et al. (35), who demonstrated that both AAF and N-OH-AAF cause an increase in intracellular levels of mRNA coding for epoxide hydrolase in rats. This finding, considered together with the magnitude and persistence of the elevation observed, strongly suggests that the increase in epoxide hydrolase activity is the result of enhanced enzyme synthesis.

The potencies of the structurally related compounds AAF, N-OH-AAF, and AF for inducing epoxide hydrolase activity reflect their hepatocarcinogenic potencies. N-OH-AAF, which is more hepatocarcinogenic than AAF in the rat (36) yielded an ED[50] of ~12 mg/kg versus 20 mg/kg for AF. The less potent hepatocarcinogen AF (37,38) elicited a relatively small increase in epoxide hydrolase activity (240% of control), and no dose-response relationship over the range of doses employed.

Hepatic epoxide hydrolase was not inducible by AAF in guinea pigs, mice, or Cotton rats, or by N-OH-AAF in guinea pigs. This reflects the hepatocarcinogenic potency of these compounds in these species (21,23). The strain and species differences in susceptibility to AAF-induced hepatocarcinogenesis have been attributed to variations in the metabolic activation of this compound. Guinea pigs are lacking in sulfotransferase activity, and also readily convert N-OH-AAF to 7-OH-2-acetylaminofluorenone, which is inactive as a carcinogen (39). Cotton rats possess 5 times the AAF-N-hydroxylation activity, 3 times the N-OH-AAF-deacetylation activity, but only 1/3 the N-OH-AAF-sulfotransferase activity of Sprague-Dawley rats (23). It is probable that the lack of AAF-dependent epoxide hydrolase induction observed in these animals is related to this altered pattern of AAF metabolism. The results are consistent with the hypothesis that formation of the N-O-sulfate conjugate of N-OH-AAF is necessary for epoxide hydrolase elevation by this compound. Mice possess very low levels of AAF-N-hydroxylase activity (22,40). The lack of epoxide hydrolase increase in response to AAF in this species is likely a reflection of the low rate of formation of N-OH-AAF.

The results presented support the hypothesis that AAF dependent increases in epoxide hydrolase activity are the result of enzyme induction. The relative potencies of AAF, N-OH-AAF, and AF for inducing epoxide hydrolase reflect the hepatocarcinogenicity of these compounds. The extent of epoxide hydrolase elevation by AAF is related to its hepatocarcinogenic potency in several species and strains. These observations provide further support for the hypothesis that a relationship exists between hepatocarcinogenic potency and increases in epoxide hydrolase. Furthermore, these data, considered together with subsequent studies involving modulation of AAF metabolism (Graichen and Dent, manuscript in preparation), support the suggestion that metabolic activation of AAF to N-OH-AAF and the subsequent conjugation of N-OH-AAF with sulfate are required for AAF to elicit increases in epoxide hydrolase activity.

Acknowledgements

We wish to express our appreciation to Stephanie Schnell and Doug Neptun for excellent technical assistance and Drs. James Popp and Thomas Leonard for many useful discussions.

References

1. Dent, J.G. and Graichen, M.E. (1982), Effect of hepatocarcinogens on epoxide hydrolase and other xenobiotic metabolizing enzymes, Carcinogenesis, 3, 733-738.
2. Kaderbhai, M.A., Bradshaw T.K. and Freedman, R.B. (1982), Alterations in the enzyme activity and polyepitope composition of rat hepatic endoplasmic reticulum during acute exposure to 2-acetylaminofluorenone, Chem.-Biol. Interactions, 39, 279-299.
3. Aström, A. and DePierre, J.W. (1981), Characterization of the induction of drug-metabolizing enzymes by 2-acetylaminofluorenone, Biochem. Biophys. Acta, 673, 225-233.
4. Sharma, R.N., Guroo, H.J., Furber, E., Murray, R.K. and Cameron, R.G. (1981), Effects of hepatocarcinogens and hepatocarcinogenesis on the activity of rat liver microsomal epoxide hydrolase and observations on the electrophoretic behavior of this enzyme, Cancer Res., 41, 3311-3319.
5. Boelsteri, U.A., Romagna, F., Viviani, A. and Zhinden, G. (1982), Epoxide hydrolase activity in small biopsy samples of preneoplastic and neoplastic rat liver, Toxicol. Lett., 13, 119-124.
6. Okita, K., Kligman, L.H. and Furber, E. (1975), A new common marker for premalignant hepatocytes induced in the rat by chemical carcinogens, J. Natl. Cancer Inst., 54, 199-202.
7. Griffin, M.J. and Kizer, D.E. (1978), Purification and quantitation of preneoplastic antigen from hyperplastic nodules and normal liver, Cancer Res., 38, 1136-1141.
8. Levin, W., Lu, A.Y.H., Thomas, P.E., Ryan, D., Kizer, D.E. and Griffin, M.J. (1978), Identification of epoxide hydrolase as the preneoplastic antigen in rat liver hyperplastic nodules, Proc. Natl. Acad. Sci. USA, 75, 3249-3254.
9. Lin, J.C., Kligman, L. and Furber, E. (1980), Purification and partial characterization of a preneoplastic antigen in liver carcinogenesis, Cancer Res., 40, 3755-3762.
10. Novikoff, A.B., Novikoff, P.M., Stockert, R.J., Becker, F.F., Yam, A., Prouchnysky, M.S., Levin, W. and Thomas, P.E. (1979), Immunocytochemical localization of epoxide hydride in hyperplastic nodules induced in rat liver of 2-acetylaminofluorenone, Proc. Natl. Acad. Sci. USA, 76, 5207-5211.
11. Oesch, F., Vogel-Bindel, U., Guenther, T.M., Cameron, R. and Furber, E. (1983), Characterization of microsomal epoxide hydrolase in hyperplastic liver nodules of rats, Cancer Res., 43, 313-319.
12. Leonard, T.B., Dent, J.G., Graichen, M.E., Lyght, O. and Popp, J.A. (1982), Comparison of hepatic initiation-promotion systems, Carcinogenesis, 3, 851-856.
13. Griffin, M.J. and Noda, K.-I. (1980), Quantitation of epoxide hydrolase released from hyperplastic nodules and hepatoma micromesomes, Cancer Res., 40, 2768-2773.
14. Irving, C.C. (1979), Species and tissue variations in the metabolic activation of aromatic amines, in Griffin, C.A., Shaw, C.R. (eds.), Carcinogens: Identification and Mechanisms of Action, Raven Press, NY, pp. 211-227.
15. Miller, J.A. and Miller, E.C. (1969), The metabolic activation of carcinogenic aromatic amines and amides, Proc. Exp. Tumor Res., 11, 273-301.
16. Weisburger, J.H. and Weisburger, E.K. (1973), Biochemical formation and pharmacological, toxicological, and pathological properties of hydroxylamines and hydroxamic acids, Pharmacol. Rev., 25, 1-66.
17. Thorgeransson, S.S., Jollow, D.J., Sasame, H.A., Green, I. and Mitchell, J.R. (1973), The role of cytochrome P-450 in N-hydroxylation of 2-acetylaminofluorenone, Mol. Pharmacol., 9, 598-604.
18. Bartsch, H., Dworin, M., Miller, J.A. and Miller, E.C. (1972), Electrophilic N-acetoxyaminoazoles derived from carcinogenic N-hydroxyl-N-acetylarnilnoazoles by enzymatic deacetylation and transacetylation in
M.E. Graichen and J.G. Dent

Liver, Biochim. Biophys. Acta, 286, 272-298.

19. Debaun, J.R., Miller, E.C., and Miller, J.A. (1970), N-hydroxy-2-acetylaminofluorene sulfotransferase: its probable role in carcinogenesis and in protein-(methion-S-yl) binding in rat liver, Cancer Res., 30, 577-595.

20. King, C.M. (1974), Mechanism of reaction, tissue distribution, and inhibition of arylhydroxamic acid acetyltransferase, Cancer Res., 34, 1503-1515.

21. Miller, E.C., Miller, J.A., and Enomoto, M. (1964), The comparative carcinogenicities of 2-acetylaminofluorene and its N-hydroxy metabolite in mice, hamsters, and guinea pigs, Cancer Res., 24, 2018-2032.

22. Thorgeirsson, S.S., Felton, J.S., and Nebert, D.W. (1975), Genetic differences in the aromatic hydrocarbon-inducible N-hydroxylation of 2-acetylaminofluorene and acetaminophen-produced hepatotoxicity in mice, Mol. Pharmacol., 11, 159-165.

23. Schut, H.A.J. and Thorgeirsson, S.S. (1978), In vitro metabolism and mutagenic activation of 2-acetylaminofluorene by subcellular liver fractions from Cotton rats, Cancer Res., 38, 2501-2507.

24. Solt, D.B., Medline, A., and Farber, E. (1977), Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis, Am. J. Pathol., 88, 595-628.

25. Schmassmann, H.U., Glatt, H.R., and Oesch, F. (1976), A rapid assay for epoxide hydratase activity with benzo[a]pyrene-4,5-(K-region)-oxide as substrate, Anal. Biochem., 74, 94-104.

26. Oesch, F., Jerina, D.M., and Daly, J. (1971), A radiometric assay for hepatic epoxide hydratase activity [7-3H]stylene oxide, Biochem. Biophys. Acta, 227, 685-691.

27. Jerina, D.M., Dansette, P.M., Lu, A.Y.H., and Levin, W. (1977), Hepatic microsomal epoxide hydrolase: a sensitive radiometric assay for hydration of arene oxides of carcinogenic aromatic hydrocarbons, Mol. Pharmacol., 13, 342-351.

28. Dent, J.G., Graichen, M.E., Roth, R.W., and Heys, J.R. (1981), A radiometric assay for methyl red azoreductase-DT diaphorase, Anal. Biochem., 112, 299-303.

29. Gornall, R.J., Bardawill, C.J., and David, M.M. (1949), Determination of serum proteins by means of the Biuret reaction, J. Biol. Chem., 177, 751-766.

30. Steel, R.G.D. and Torrie, J.H. (1960), Principles and Procedures of Statistics, published by McGraw-Hill, New York, NY.

31. Ota, K. and Hammock, B.D. (1980), Cytosolic and microsomal epoxide hydrolases: differential properties in mammalian liver, Science, 207, 1479-1481.

32. Guenther, T.M. and Oesch, F. (1982), A new microsomal epoxide hydrolase, The Pharmacologist, 24, 127.

33. Schor, N.A. and Boh, E. (1977), Rat liver post-microsomal D-T diaphorase: activation of the enzymes by two carcinogens, Res. Comm. Clin. Pathol. Pharmacol., 16, 179-182.

34. Schmassmann, H., and Oesch, F. (1978), Trans-stilbene oxide: a selective inducer of rat liver epoxide hydrolase, Mol. Pharmacol., 14, 834-847.

35. Gonzalez, F.J., Samore, M., McQuiddy, P., and Kasper, C.B. (1982), Effects of 2-acetylaminofluorene and N-hydroxy-2-acetylaminofluorene on cellular levels of epoxide hydrolase, cytochrome P-450 b, and NADPH-cytochrome c (P-450) oxidoreductase messenger ribonucleic acids, J. Biol. Chem., 257, 11032-11036.

36. Miller, E.C., Miller, J.A., and Hartmann, H.A. (1961), N-hydroxy-2-acetylaminofluorene: a metabolite of 2-acetylaminofluorene with increased carcinogenic activity in the rat, Cancer Res., 21, 815-824.

37. Morris, H.P., Dubnik, C.S., and Johnson, J.M. (1950), Studies of the carcinogenic action in the rat of 2-nitro-, 2-amino-, 2-acetaminofluorene, and 2-diacetylaminofluorene after ingestion and after painting, J. Natl. Cancer Inst., 10, 1201-1213.

38. Miller, J.A., Sandin, R.B., Miller, E.C., and Rusch, H.P. (1955), The carcinogenicity of compounds related to 2-acetylaminofluorene. II. Variations in the bridges and the 2-substituent, Cancer Res., 13, 188-199.

39. Razzouk, C., Batardy-Gregoire, M., and Roberfroid, M. (1982), Metabolism of N-hydroxy-2-acetylaminofluorene and N-hydroxy-2-acetylaminofluorene by guinea pig liver microsomes, Cancer Res., 42, 4712-4718.

40. Razzouk, C., Batardy-Gregoire, M., and Roberfroid, M. (1982), Genetic differences in the enzyme properties of the aromatic hydrocarbon inducible N-hydroxylation of 2-acetylaminofluorene in mouse liver, Carcinogenesis, 3, 1325-1329.

(Received on 10 June 1983; accepted on 1 October 1983)